View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Michiel Declercq ... (+5)
  • Michiel Declercq
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
Thomas Vranken
  • Thomas Vranken

argenx FIRST LOOK: Amgen's Phase 3 MG data

Competitor Amgen announced topline results from its Phase 3 MINT study with Uplizna in generalised myasthenia gravis. We note the suggested semi-annual dosing frequency and solid clinical improvements, but still consider Vyvgart to be the top contender in an increasingly crowded space. We reiterate our € 530 TP and Accumulate rating for argenx.

Guy Sips
  • Guy Sips

Barco We took ‘One Look' at Barco an decided to lower the barrier

In 1H24, Barco's business was impacted by customer destocking in the Meeting Experience and Healthcare segments. In Entertainment, customers delayed investments as a result of a weak film slate and in anticipation of Barco's upcoming product launches. While visibility remains low, Barco has reason to look forward to a very different 2H24. But we now think it will be even more back-end loaded and somewhat milder than we originally expected. We maintain our positive stance - albeit with a slight...

D`ieteren Group: 1 director

A director at D`ieteren Group bought 1,300 shares at 197.959EUR and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Guy Sips ... (+5)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Michiel Declercq
  • Wim Lewi
 PRESS RELEASE

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE...

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP September 19, 2024 – 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology co...

Argen X SE: 1 director

A director at Argen X SE sold 924 shares at 495.250EUR and the significance rating of the trade was 84/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

Sharad Kumar S.P
  • Sharad Kumar S.P

Holdings Report - August 2024 KBCS Holdings Universe Up 0.5% Thanks To...

1M Performance - Absolute: During July'24 (1M period), the KBCS Holdings Universe posted a return of 0.5% which was mainly driven by multi-asset holdings (+1.7%) while single-asset holdings posted a negative return of -1.3%. The 3 top performers during the period were HAL Trust (+5.1%), Texaf (+2.9%), and The Infrastructure Company (TINC, +9.6%) while the 3 worst performers were Brederode (-2.8%), Solvac (-5.3%), and Whitestone Group (-7.2%). YTD Performance - Relative: On a YTD basis (as of A...

Michiel Declercq
  • Michiel Declercq

D'Ieteren Shareholder shift & extraordinary dividend in focus after go...

D'Ieteren reported a good set of 1H24 results, with the adj. PBT (gs) up 6.4% to € 586m (kbcse: € 572m, css: € 546m), while FCF (gs) improved materially to € 540m (1H23: € 187m). The group also confirmed its outlook. More important was the shareholder reorganisation, with Nayarit to acquire 16.7% from SPDG. Secondly, D'Ieteren announced the proposal of an extraordinary dividend of € 74 per share. Buy and € 260 TP reiterated.

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ING Benelux Conference London Alfen Fugro Renewi Other company news D'Ieteren: €4bn dividend, family shareholder reorganization, good results Euronext: Continued Momentum Staffing: French staffing: underlying July trend weak; August outlook slightly better Events Calendar

Jacob Mekhael ... (+3)
  • Jacob Mekhael
  • Michiel Declercq
  • Wim Lewi
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ING Benelux Conference London: Aalberts, Arcadis, Azelis, Barco, Basic-Fit, Brunel International, DEME Group, Euronext, Fagron, Heijmans, Kinepolis, Lotus Bakeries, Melexis, Ontex, Randstad, Recticel, SBM Offshore, TKH Group, Van Lanschot Kempen Other company stories - OCI: Divestment of Methanol to Methanex for US$2.05bn, Staffing: US August temp volumes marginally better trend; NFP jobs miss

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

D'Ieteren: 1H24 preview. Sofina: Purpose achieved, patience confirmed

Guy Sips ... (+11)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update September 2024 –Cofinimmo & Kinepolis in;...

In this September update of our Dynamic Top Pick List we make 4 changes. •We include Cofinimmo in our Dynamic Top Pick List after our recent upgrade from Accumulate to Buy. We expect the name to outperform in a decreasing interest rate environment given its relatively high leverage and cheap valuation. We also believe the risk of a dilutive equity raise eased when the FY24 capex decreased from € 320m to € 250m. The management stays disciplined in its capex program and continues to focus on asse...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

D'Ieteren: Very poor August Belgium car figures, down 20%, VW down 31%. Gimv: 1Q24/25 platform portfolio return in line with long-term return target. Coverage change

 PRESS RELEASE

argenx to Present at Upcoming Investor Conferences

argenx to Present at Upcoming Investor Conferences August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September: 2024 Wells Fargo Healthcare Conference. Fireside chat on Wednesday, September 4, 2024 at 1:30 p.m. ET in Boston, MA.Morgan Stanley 22nd Annual Global Healthcare Conference. Fireside chat on Thursday, September 5, 2024 at 4:50 p.m....

Thijs Berkelder
  • Thijs Berkelder

Alfen : New strategic plan takes longer than we hoped for

>Feedback analyst conference call - No new equity needed. CEO confirms Alfen does not expect it will need new capitalGuidance Q3 revenues per segment. Now guiding for EV Charging Q3 lower than Q2 (previously sequential rise) and stronger Q4, for Energy Storage Q3 similar as Q1 and stronger Q4 again, for Smart Grids a Q3 similar to Q2 and stronger Q4. Our view: impression of lower outlook for EV Charging and Smart Grids vs. higher in Energy Storage.Ramp-up su...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

AEGON: a story of core vs non-core. Alfen: Arranges 3Q waiver ahead of 4Q strategic update and restructuring plan. Deceuninck: Strong beat on EBITDA, driven by Turkey. Kinepolis: EBITDAL miss on operating leverage, cash flow in line. Van Lanschot Kempen: Strong 1H24 results

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch